ARMP Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of --. Armata Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Armata Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 281.36%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Armata Pharmaceuticals has higher upside potential than Perspective Therapeutics, analysts believe Armata Pharmaceuticals is more attractive than Perspective Therapeutics.

Armata Pharmaceuticals has a beta of 0.938, which suggesting that the stock is 6.224% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Armata Pharmaceuticals's net income of -$6.5M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 1,000.03x versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 12.06%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 16.57%.

Armata Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 281.36%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

Armata Pharmaceuticals has a beta of 0.938, which suggesting that the stock is 6.224% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Armata Pharmaceuticals's net income of -$6.5M is lower than Electromed's net income of $1.9M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 1,000.03x versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of -35.79%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

Armata Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 281.36%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 879.02%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.938, which suggesting that the stock is 6.224% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Armata Pharmaceuticals's net income of -$6.5M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 35.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 1,000.03x versus 2.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Armata Pharmaceuticals's net margin of 0.18%. Armata Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Armata Pharmaceuticals has a consensus price target of $9.00, signalling upside risk potential of 281.36%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Armata Pharmaceuticals has higher upside potential than Xtant Medical Holdings, analysts believe Armata Pharmaceuticals is more attractive than Xtant Medical Holdings.

Armata Pharmaceuticals has a beta of 0.938, which suggesting that the stock is 6.224% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Armata Pharmaceuticals's net income of -$6.5M is lower than Xtant Medical Holdings's net income of $58K. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 1,000.03x versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.